THNR vs. CNCR

Last updated Jul 14, 2026

THNR (Amplify Weight Loss Drug & Treatment ETF) and CNCR (Loncar Cancer Immunotherapy ETF) are both Health & Biotech Equities funds - THNR tracks the VettaFi Weight Loss Drug & Treatment Index while CNCR tracks the Loncar Cancer Immunotherapy Index. Both are passively managed. THNR charges 0.59%/yr vs 0.79%/yr for CNCR.

Performance

THNR vs. CNCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Amplify Weight Loss Drug & Treatment ETF (THNR) and Loncar Cancer Immunotherapy ETF (CNCR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

THNR

• 1D: -1.11%
• 1M: 4.99%
• 6M: -2.05%
• YTD: 1.67%
• 1Y: 13.44%
• 3Y*: —
• 5Y*: —
• 10Y*: —

CNCR

• 1D: 0.00%
• 1M: 0.00%
• 6M: —
• YTD: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

THNR vs. CNCR - Yearly Performance Comparison

	2026 (YTD)
THNR Amplify Weight Loss Drug & Treatment ETF	1.11%
CNCR Loncar Cancer Immunotherapy ETF	0.00%

THNR vs. CNCR - Sectors Allocation Comparison

Sectors	THNR	CNCR
Healthcare	99.3%	96.6%
Financial Services	0.8%	3.3%
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

THNR vs. CNCR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

THNR

THNR Risk / Return Rank: 25
THNR Sharpe Ratio Rank: 24
THNR Sortino Ratio Rank: 25
THNR Omega Ratio Rank: 23
THNR Calmar Ratio Rank: 28
THNR Martin Ratio Rank: 24

CNCR

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

THNR vs. CNCR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Amplify Weight Loss Drug & Treatment ETF (THNR) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	THNR	CNCR	Difference
Sharpe ratio: Return per unit of total volatility	0.70	—	—
Sortino ratio: Return per unit of downside risk	1.14	—	—
Omega ratio: Gain probability vs. loss probability	1.13	—	—
Calmar ratio: Return relative to maximum drawdown	1.12	—	—
Martin ratio: Return relative to average drawdown	2.43	—	—

Drawdowns

THNR vs. CNCR - Drawdown Comparison

The maximum THNR drawdown since its inception was -32.51%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for THNR and CNCR.

Drawdown Indicators

	THNR	CNCR	Difference
Max Drawdown Largest peak-to-trough decline	-32.51%	0.00%	-32.51%
Max Drawdown (1Y) Largest decline over 1 year	-12.06%	—	—
Current Drawdown Current decline from peak	-6.69%	0.00%	-6.69%
Average Drawdown Average peak-to-trough decline	-12.06%	0.00%	-12.06%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.54%	—	—

Volatility

Volatility by Period

	THNR	CNCR	Difference
Volatility (1M) Calculated over the trailing 1-month period	5.61%	—	—
Volatility (6M) Calculated over the trailing 6-month period	14.13%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	19.36%	0.00%	+19.36%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	19.40%	0.00%	+19.40%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	19.40%	0.00%	+19.40%

THNR vs. CNCR - Expense Ratio Comparison

THNR has a 0.59% expense ratio, which is lower than CNCR's 0.79% expense ratio.

Dividends

THNR vs. CNCR - Dividend Comparison

THNR's dividend yield for the trailing twelve months is around 1.61%, while CNCR has not paid dividends to shareholders.

Position	TTM	2025	2024
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%
THNR Amplify Weight Loss Drug & Treatment ETF	1.61%	1.64%	0.98%

Frequently Asked Questions

Which ETF is better, THNR or CNCR?

On fees, THNR is cheaper at 0.59% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, THNR or CNCR?

THNR is cheaper with a 0.59% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, THNR or CNCR?

THNR has the higher dividend yield at 1.61%, compared with 0.00% for CNCR.

What is the main difference between THNR and CNCR?

THNR tracks VettaFi Weight Loss Drug & Treatment Index, while CNCR tracks Loncar Cancer Immunotherapy Index. They also come from different issuers: Amplify and Exchange Traded Concepts. Their fees differ too: 0.59% for THNR and 0.79% for CNCR.